Free Trial

Genenta Science (GNTA) Stock Price, News & Analysis

Genenta Science logo
$3.93 -0.04 (-1.01%)
Closing price 04/1/2025 03:59 PM Eastern
Extended Trading
$3.93 0.00 (-0.08%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Genenta Science Stock (NASDAQ:GNTA)

Key Stats

Today's Range
$3.78
$3.97
50-Day Range
$3.52
$4.37
52-Week Range
$2.20
$7.28
Volume
7,415 shs
Average Volume
14,721 shs
Market Capitalization
$71.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00
Consensus Rating
Buy

Company Overview

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

Remove Ads

Genenta Science Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
60th Percentile Overall Score

GNTA MarketRank™: 

Genenta Science scored higher than 60% of companies evaluated by MarketBeat, and ranked 427th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Genenta Science has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Genenta Science has received no research coverage in the past 90 days.

  • Read more about Genenta Science's stock forecast and price target.
  • Earnings Growth

    Earnings for Genenta Science are expected to decrease in the coming year, from ($0.93) to ($1.07) per share.

  • Price to Book Value per Share Ratio

    Genenta Science has a P/B Ratio of 3.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Genenta Science's valuation and earnings.
  • Percentage of Shares Shorted

    0.01% of the float of Genenta Science has been sold short.
  • Short Interest Ratio / Days to Cover

    Genenta Science has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Genenta Science has recently decreased by 13.33%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Genenta Science does not currently pay a dividend.

  • Dividend Growth

    Genenta Science does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.01% of the float of Genenta Science has been sold short.
  • Short Interest Ratio / Days to Cover

    Genenta Science has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Genenta Science has recently decreased by 13.33%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Genenta Science has a news sentiment score of 1.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Genenta Science this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Genenta Science insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    28.99% of the stock of Genenta Science is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 15.13% of the stock of Genenta Science is held by institutions.

  • Read more about Genenta Science's insider trading history.
Receive GNTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genenta Science and its competitors with MarketBeat's FREE daily newsletter.

GNTA Stock News Headlines

Genenta Science announces EUR 20M financing to expand pipeline
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Genenta Science SpA ADR
See More Headlines

GNTA Stock Analysis - Frequently Asked Questions

Genenta Science's stock was trading at $4.35 at the beginning of the year. Since then, GNTA stock has decreased by 9.7% and is now trading at $3.93.
View the best growth stocks for 2025 here
.

Genenta Science (GNTA) raised $28 million in an IPO on Wednesday, December 15th 2021. The company issued 2,400,000 shares at $10.50-$12.50 per share.

Shares of GNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Genenta Science investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), PDD (PDD) and AppLovin (APP).

Company Calendar

Today
4/01/2025
Next Earnings (Estimated)
4/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GNTA
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$25.00
High Stock Price Target
$25.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+536.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.21 per share
Price / Book
3.25

Miscellaneous

Free Float
12,988,000
Market Cap
$71.88 million
Optionable
Not Optionable
Beta
0.71
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:GNTA) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners